Repertoire Genesis

is a Japan-based biotechnology company that develops and commercializes T-cell receptors to treat cancer...
Read more

Repertoire Genesis

is a Japan-based biotechnology company that develops and commercializes T-cell receptors to treat cancer...
Read more

Repertoire Genesis News

Repertoire Genesis's News
May 31, 2022Biospectrum Asia

Eurofins enhances clinical and biopharma services in Japan

Eurofins enhances clinical and biopharma services in Japan... See more »
Repertoire Genesis's News

Repertoire Genesis Headquarters

Saito Bioincubator 402,7-7-15 Saito-asagi

Ibaraki-shi, Ōsaka Prefecture567-0085

Driving Directions »

Repertoire Genesis Summary

ABOUT

Overview

Repertoire Genesis is a Japan-based biotechnology company that develops and commercializes T-cell receptors to treat cancer. Repertoire Genesis was founded in 2014. Repertoire Genesis' headquarters is located in Ibaraki-shi, Ōsaka Prefecture, JP 567-0...

Acquisitions

There have been no acquisitions found related to Repertoire Genesis

Funding

Funding data cannot be found related to Repertoire Genesis

Investments

Recent investment data cannot be found related to Repertoire Genesis

Frequently Asked Questions about Repertoire Genesis

  1. When was Repertoire Genesis founded?

    Repertoire Genesis was founded in 2014
  2. Who is Repertoire Genesis's CEO?

    Repertoire Genesis's CEO is Mitsuo Ichikawa
  3. How much revenue does Repertoire Genesis generate?

    Repertoire Genesis generates $3.5M in revenue
  4. How much funding does Repertoire Genesis have?

    Repertoire Genesis has historically raised $0 in funding
  1. Where is Repertoire Genesis's headquarters?

    Repertoire Genesis's headquarters is in Ibaraki-shi Ōsaka Prefecture, JP
  2. How many employees does Repertoire Genesis have?

    Repertoire Genesis has 78 employees
  3. What sector does Repertoire Genesis operate in?

    Repertoire Genesis is in Biotechnology
  4. Who are Repertoire Genesis's competitors?

    Repertoire Genesis's top competitors are CARsgen, Abbisko, JW Therapeutics

Trending Companies